Novotech awarded CRO Best Practice Award
27 February, 2015Sydney-based contract research organisation (CRO) Novotech has been awarded the CRO Best Practice Award for the third time in recent years by Frost & Sullivan.
Australian Innovation System Report released
26 February, 2015Innovation is key for Australian businesses to remain competitive according to the latest Australian Innovation System Report, which has been released by the office of the Chief Economist and the Department of Industry and Science.
Phylogica lines up EU patent for Phylomer screening
25 February, 2015 by Dylan Bushell-EmblingPhylogica (ASX:PYC) has been issued a notice of allowance for an EU patent covering using its Phylomer peptide libraries for drug discovery screening.
Phosphagenics to sell bioElixia business
25 February, 2015 by Dylan Bushell-EmblingPhosphagenics (ASX:POH) has put its bioElixia range of cosmetic products up for sale as part of plans to focus on its core drug delivery business.
AusBiotech comments on draft IP Toolkit for research collaboration
24 February, 2015AusBiotech has made a submission to IP Australia on the draft IP Toolkit for research collaborations between research institutes and companies, where it said the draft IP Toolkit could offer useful guidance to SMEs who wish to engage in collaborations.
Anatara Lifesciences names new CEO
24 February, 2015 by Dylan Bushell-EmblingAnatara Lifesciences (ASX:ANR) has made three new executive appointments including a new CEO and has reported a 530% increase in its net loss for the first half of FY15.
Saluda raises $10m for neuromodulation device
23 February, 2015 by Dylan Bushell-EmblingNICTA spinoff Saluda Medical has raised $10m in Series B funding to help develop Evoke, its neuromodulation device for treating chronic pain and other conditions.
Replacing leaky heart valves in situ
23 February, 2015Surgeons in Sydney have successfully replaced leaky mitral valves in two human hearts while they were still beating.
Annual survey of Australia's biotech industry closing soon
19 February, 2015The annual AusBiotech CEO Industry Position Survey is in its final weeks of data collection and biotech industry leaders (CEOs, MDs) are urged to assist industry development with experiences, knowledge, key metrics and political insight.
Anatara's Detach reduces piglet mortality in farm trial
18 February, 2015 by Dylan Bushell-EmblingAnatara Lifesciences (ASX:ANR) said its Detach product was able to reduce piglet mortality compared with a placebo during an on-site trial at a Victorian farm.
Call for transitional arrangements for R&D Tax incentive cap
17 February, 2015The passage of legislation last week to cap claims on the Research and Development (R&D) Tax Incentive and its retrospective application to 1 July 2014 has prompted calls for the government to provide transitional arrangements for biotech companies abandoned in a difficult position.
Starpharma 1H losses grow on trial spending
17 February, 2015 by Dylan Bushell-EmblingStarpharma (ASX:SPL) reported a wider net loss for the first half of FY15 on increased clinical trial spending, but a capital raising left the company in an improved cash position.
Immuron licenses Travelan in China region
17 February, 2015 by Dylan Bushell-EmblingImmuron (ASX:IM) has licensed its Travelan product - a preventative treatment for travellers diarrhoea - in China and expects the market to eclipse sales of the product in its other regions combined.
PolyNovo names new CEO
16 February, 2015 by Dylan Bushell-EmblingPolyNovo (ASX:PNV) has appointed a new CEO and a regulatory affairs manager as it pursues commercialisation of its products in areas including wound and burns treatment.
CSL boosts half-year profit by 7%
13 February, 2015 by Dylan Bushell-EmblingCSL (ASX:CSL) has reported a net profit for the first half of FY15 of $890.3m, with sales increasing across all its core product segments.
